CTSA Diversity Supplement - Vielot - Effectiveness of Recombinant Herpes Zoster Vaccine in Older U.S. Adults

CTSA 多样性补充 - Vielot - 重组带状疱疹疫苗对美国老年人的有效性

基本信息

批准号：
10294412
负责人：
John Bernard Buse
金额：
$ 17万
依托单位：
UNIV OF NORTH CAROLINA CHAPEL HILL
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-06-01 至 2023-02-28
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10294412
关键词：
Academia Address Adjuvant Adolescence Adolescent Adrenal Cortex Hormones Adult Advisory Committees Age Age-Years Agreement Algorithms Anatomy Applications Grants Area Autoimmune Diseases Autologous Award Biological Biological Products Black race Blindness COVID-19 pandemic COVID-19 vaccine Cardiovascular Diseases Caring Case Study Centers for Disease Control and Prevention (U.S.)Characteristics Chemicals Chickenpox Classification Clinical Clinical Management Clinical Medicine Clinical Research Clinical Sciences Clinical Trials Code Cohort Studies Collaborations Communicable Diseases Communication Comparative Effectiveness Research Consult Consultations Cox Models Current Procedural Terminology Codes Data Data Analyses Data Collection Data Science Data Set Data Sources Databases Detection Development Development Plans Diabetes Mellitus Diagnosis Discipline Disease Disease-Modifying Second-Line Drugs Disseminated Malignant Neoplasm Doctor of Philosophy Dose Drug Industry Drug Prescriptions Educational process of instructing Educational workshop Effectiveness Elderly Electronic Health Record Emergency Situation End stage renal failure Enrollment Epidemiologic Methods Epidemiologist Epidemiology Equipment Ethics Committees Ethnic Origin Evaluation Event Exercise Faculty Family Practice Fee-for-Service Plans Feedback Funding Future Geographic Locations Geography Goals Gold Government Grant HIV Health Health Care Seeking Behavior Health Personnel Health Policy Health Services Health Services Research Health Status Health system Healthcare Healthcare Systems Hematologic Neoplasms Hematopoietic Stem Cell Transplantation Herpes Zoster Ophthalmicus Herpes zoster disease Hospitals Hour ICD-9 Immunization Immunocompetence Immunocompetent Immunocompromised Host Immunosuppression Immunosuppressive Agents Incidence Individual Industry Infant Infection Informatics Inpatients Institutes Institutional Review Boards Insurance Claim Review Interdisciplinary Study International International Classification of Diseases Intervention K-Series Research Career Programs Lead Leadership Learning Licensure Life Cycle Stages Light Link Longevity Longitudinal Studies Malignant Neoplasms Manuscripts Maps Measures Medical Medicare Medicare Part A Medicare claim Medicine Mentors Mentorship Methodology Methods Modeling Modification Monitor Multi-Institutional Clinical Trial North Carolina Obesity Observation in research Older Population Opioid Oral Organ Transplantation Outcome Outcomes Research Outpatients Pain Parents Participant Patients Pattern Peer Group Peer Review Perinatal Infection Persistent pain Persons Pharmaceutical Preparations Pharmacoepidemiology Pharmacologic Substance Pharmacy facility Policies Population Population Heterogeneity Positioning Attribute Postdoctoral Fellow Postherpetic neuralgia Predictive Value Pregnant Women Preventive healthcare Primary Health Care Procedures Process Program Development Protocols documentation Proxy Public Health Public Policy Publications Race Randomized Reading Recombinants Recommendation Records Reference Standards Regulation Research Research Design Research Institute Research Methodology Research Personnel Research Project Grants Research Training Resources Respiratory syncytial virus Risk Risk Management Role Rotation Safety Safety Management Sampling Science Scientist Secure Series Services Societies Solid Specialist Statistical Data Interpretation Statistical Methods Streptococcus Group B Structure Students Study Section Subgroup Subunit Vaccines Syndrome TNFSF15 gene Testing Therapeutic Time TimeLine Trainers Training Training Translating Translational Research Translations Transplant Recipients Underrepresented Populations United States United States Centers for Medicare and Medicaid Services United States Food and Drug Administration United States National Institutes of Health Universities Update Use Effectiveness Vaccinated Vaccination Vaccine Clinical Trial Vaccines Validation Visit Vulnerable Populations Woman Work Workforce Development Writing Zoster Vaccine age group base beneficiary career career development causal model chemotherapy clinical Diagnosis cohort community intervention community organizations comorbidity comparative effectiveness comparison group congenital immunodeficiency data access data dissemination data warehouse disability doctoral student effectiveness evaluation effectiveness study efficacy trial epidemiology study evidence base experience faculty mentor faculty support follow-up frailty graduate student hazard health care service health care service utilization health data health disparity high risk population human old age (65+)immunogenic immunogenicity improved indexing infancy informatics tool innovation inpatient service insight insurance claims interest leukemia/lymphoma low income country medical schools medication safety meetings member neonatal infection novel novel vaccines outpatient programs pandemic disease patient health information patient subsets peer policy implication power analysis prevent primary outcome professor programs racial and ethnic reactivation from latency research and development research study responsible research conduct risk minimization secondary outcome sex skills study population symposium training opportunity vaccination outcome vaccine acceptance vaccine access vaccine development vaccine effectiveness vaccine efficacy vaccine evaluation vaccine safety vaccine trial virtual working group

项目摘要

Abstract/Summary of Parent Award Since inception in 2008, the UNC CTSA affiliate, the North Carolina Translational and Clinical Sciences Institute (TraCS) has transformed clinical and translational science at UNC through interdisciplinary research, training, collaboration with partners and stakeholders, and strong engagement across the CTSA consortium. We have built a dynamic regional network of universities, research institutes, health care providers, and >130 community organizations across our state. In the current funding period, we have added NC State University to RTI International and NC A&T University as full partners in our CTSA hub. In the funding period 2013-2023, our goal is to translate the best science from UNC and across the CTSA consortium into creative, effective, and accessible clinical and community interventions, addressing the public health problems of our state and advancing national CTSA goals. We accomplish through 5 aims: Aim 1. Workforce Development: Develop and support a skilled and diverse clinical and translational research workforce to advance translational innovations and address healthcare priorities. Aim 2. Collaboration and Engagement: Engage diverse stakeholders as active partners in translational research, and promote innovative approaches to team science. Aim 3. Integration: Integrate translational research across the research continuum, disciplines, populations, and throughout the lifespan. Aim 4. Methods/Processes: Develop and disseminate innovative methods and approaches to address scientific and operational barriers to translating scientific findings. Aim 5. Informatics: Incorporate cutting-edge informatics tools and methodologies in every aspect of translational research. This diversity supplement application by Nadja Vielot, PhD will use real-world Medicare claims data to study the post-licensure experience in the United States with recombinant herpes zoster vaccine (RZV). The aims of the proposal are to: 1) Estimate RZV effectiveness against herpes zoster, post-herpetic neuralgia (PHN) and herpes zoster ophthalmicus (HZO) in adults ages >65, and 2) Estimate the effectiveness of RZV in individuals with altered immunocompetence. Dr. Vielot will utilize the following CTSA Program resources for the research and training plan: Comparative Effectiveness Research: This Service will facilitate the process of securing Medicare data and oversight of the analyses. Informatics and Data Science: This Service will be used as part of Aim 3 to obtain data from the Carolina Data Warehouse for Health (CDW-H) and for assistance in linking CDW-H data to Medicare claims data. Regulatory Service: Dr. Vielot will use this service for guidance on completing the appropriate IRB and data use agreements required for the project. Workforce Development Program: Dr. Vielot will participate in the following WD training opportunities: TraCS Professional Development Seminar, R Writing Group, Mentor Training, and training in requirements for rigor. KL2 Program: Dr. Vielot will participate in the K Seminar; a seminar comprised of TraCS-funded KL2 awardees and selected individual K awardees. During this interdisciplinary seminar, she will hone her communication skills, receive feedback on work in progress including input from clinicians about the potential clinical and policy implications of her work, identify collaborators for future work, practice peer review skills, and network with a peer group of interdisciplinary scientists. TL1 Program: The TraCS TL1 Program consists of 3 tracks, 1 of which supports postdocs who wish to translate research results into health systems and policy. Dr. Vielot will participate in the TL1 "Tales of Translation" series which features experts from academia, industry and government discussing pivotal points in their careers, important research projects, and their views on opportunities and challenges when translating research results into policy. In addition, Dr. Vielot will attend either the virtual or in-person annual Translational Science meeting.

家长奖摘要/摘要自 2008 年成立以来，北卡罗来纳大学 CTSA 附属机构北卡罗来纳州转化与临床科学研究所 (TraCS) 通过跨学科研究、培训、与合作伙伴和利益相关者的合作，以及整个 CTSA 联盟的大力参与。我们有建立了一个由大学、研究机构、医疗保健提供者和超过 130 个社区组成的充满活力的区域网络我们州各地的组织。在当前资助期间，我们已将北卡罗来纳州立大学添加到RTI中 International 和 NC A&T 大学是我们 CTSA 中心的全面合作伙伴。在2013-2023年的资助期内，我们的目标就是将 UNC 和 CTSA 联盟的最佳科学成果转化为创造性、有效且易于理解的成果临床和社区干预措施，解决我们州的公共卫生问题并推动国家发展 CTSA 目标。我们通过 5 个目标来实现：目标 1. 劳动力发展：培养和支持技术熟练的人才以及多元化的临床和转化研究人员，以推进转化创新并解决医疗保健优先事项。目标 2. 协作和参与：让不同的利益相关者成为积极的合作伙伴转化研究，并促进团队科学的创新方法。目标 3. 整合：整合跨研究连续体、学科、人群和整个生命周期的转化研究。目的 4. 方法/过程：开发和传播创新方法和方法来解决科学和技术问题翻译科学发现的操作障碍。目标 5. 信息学：融合尖端信息学转化研究各个方面的工具和方法。 Nadja Vielot 博士的多样性补充应用程序将使用真实世界的医疗保险索赔数据进行研究美国重组带状疱疹疫苗 (RZV) 获得许可后的经验。的目标该提案旨在： 1) 估计 RZV 对带状疱疹、带状疱疹后神经痛 (PHN) 和 65 岁以上成人眼部带状疱疹 (HZO)，以及 2) 估计 RZV 对个体的有效性免疫能力改变。 Vielot 博士将利用以下 CTSA 计划资源进行研究及培训计划：比较有效性研究：该服务将促进保护医疗保险数据和对分析的监督。信息学和数据科学：该服务将用作目标 3 的一部分，从 Carolina Data 获取数据健康仓库 (CDW-H) 并协助将 CDW-H 数据与医疗保险索赔数据关联起来。监管服务：Vielot 博士将使用此服务来指导完成适当的 IRB 和数据项目所需的使用协议。劳动力发展计划：Vielot 博士将参加以下 WD 培训机会：TraCS 专业发展研讨会、R写作小组、导师培训，以及严格要求的培训。 KL2项目：Vielot博士将参加K研讨会； TraCS 资助的 KL2 研讨会获奖者和选定的个人 K 获奖者。在这次跨学科研讨会上，她将磨练自己的能力沟通技巧，接收正在进行的工作的反馈，包括临床医生关于潜力的意见她的工作的临床和政策影响，确定未来工作的合作者，练习同行评审技能，以及与跨学科科学家的同行小组建立联系。 TL1 计划：TraCS TL1 计划由 3 个方向组成，其中 1 个支持希望将研究成果转化为卫生系统和政策。 Vielot博士将参加TL1“Tales of 翻译”系列，学术界、工业界和政府专家讨论关键点他们的职业生涯、重要的研究项目以及他们对翻译过程中的机遇和挑战的看法研究成果转化为政策。此外，维洛特博士将参加虚拟或现场的年度转化科学会议。